Compositions and methods for inhibiting terminal transferase activity
US-9752173-B2 · Sep 5, 2017 · US
GM-CSF and IL-4 conjugates, compositions, and methods related thereto
US10093709B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10093709-B2 |
| Application number | US-201715491777-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2017 |
| Priority date | Oct 23, 2012 |
| Publication date | Oct 9, 2018 |
| Grant date | Oct 9, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer comprising administering a conjugate comprising the amino acid sequence of SEQ ID NO: 8 to a subject in need thereof, wherein the cancer is a hematological malignancy. 2. The method of claim 1 , wherein the hematological malignancy is selected from leukemia, lymphoma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia, acute monocytic leukemia (AMOL), Hodgkin's lymphomas, and non-Hodgkin's lymphomas such as Burkitt lymphoma, B-cell lymphoma and multiple myeloma. 3. A method of treating melanoma comprising administering a conjugate comprising the amino acid sequence of SEQ ID NO: 8 to a subject in need thereof.
Assignees
Inventors
Classifications
Antivirals · CPC title
Immunostimulants · CPC title
Antineoplastic agents · CPC title
Granulocyte CSF; Granulocyte-macrophage CSF · CPC title
- C07K14/5406Primary
IL-4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10093709B2 cover?
- In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression…
- Who is the assignee on this patent?
- Univ Emory, Childrens Healthcare Atlanta Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/5406. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).